Objective: Arterial stiffness is a marker of cardiovascular health. Arterial stiffness and C-reactive protein (CRP) are linked to cardiovascular outcomes. Increases in both inflammation and arterial stiffness are known to occur with menopause. The association between CRP and arterial stiffness is well accepted; however, no study has determined whether there are differences in this association by menopause status and race, independent of age.
A ging of the vascular system involves both structural and functional changes in the arterial wall that leads to stiffening of the vessel. 1 Arterial stiffness is a contributor to the age-associated increase in cardiovascular morbidity and mortality. 2, 3 Aortic pulse wave velocity (PWV), as assessed by carotid-femoral PWV, is a simple, noninvasive, and highly reproducible measure of central arterial stiffness. 4 In clinical and healthy populations, PWV is a predictor of cardiovascular and all-cause mortality. 5<9 Inflammation is a major feature in the initiation and progression of atherosclerosis and subsequent cardiovascular disease (CVD). 10, 11 Several inflammatory markers exist, but high-sensitivity C-reactive protein (CRP) is clinically advantageous because it is well validated, inexpensive, and widely available. 12 In prospective studies among healthy populations, CRP was associated with increased incidence of cardiovascular events, including death due to coronary heart disease, nonfatal myocardial infarction, peripheral vascular disease, and stroke. 13<18 Current guidelines recommend the use of CRP to further risk stratify asymptomatic adults 60 years and older who are at intermediate-risk based on a Framingham score. 19 On the other hand, among low-risk adults younger than 60 years, assessing CRP may not improve prediction beyond traditional CVD risk factors, suggesting that the association between CRP and CVD changes with age.
As women age and transition through menopause, there is an increased incidence of CVD. 20 Reduced estrogen levels that accompany menopause may trigger an inflammatory response by increasing expression and secretion of cytokines. 21 Decreased levels of estrogen may also increase arterial stiffening by altering the collagen-to-elastin ratio within the arterial wall or by inhibiting smooth muscle cell proliferation. 22, 23 Furthermore, these lower levels of estrogen are associated with increased arterial diameters and leave the vasculature more vulnerable to increasing cardiovascular risk factors. 24, 25 Therefore, menopause may act as a trigger that strengthens the relationship between inflammation and arterial stiffness and thus provides a mechanism for the increased CVD seen as women age. Menopause may consequently be the mechanism for varying utility of CRP as a cardiovascular risk factor in adult women. 19 Several studies have reported a positive association between CRP and arterial stiffness, which may be due to a direct effect of CRP on nitric oxide and endothelial function. 26<36 There is also evidence that the relationship between CRP and arterial stiffness may be stronger among older adults; however, given the evidence that both hormones and race influence CRP levels, further evaluation is needed in these populations. 37<39 The objective of this study was to examine the effect of the menopausal transition on the age-associated strengthening between CRP and PWV and the influence of race on this relationship, using the data collected among 307 African American and white women participating in the Study of Women's Health Across the Nation (SWAN) Heart Study, an ancillary study to the population-based SWAN study of the menopausal transition. This analysis will help provide a rationale for using CRP as a CVD marker and targeting middle-aged women to healthier lifestyle patterns aimed at reducing inflammation and arterial stiffening.
METHODS

Study population
SWAN is a multisite, multiethnic, longitudinal epidemiological study designed to examine the physical, psychological, and social changes that women experience during the menopausal transition. At baseline, SWAN recruited a total of 3,302 women between the ages of 42 and 52 years from seven clinical sites: Boston, MA; Chicago, IL; Detroit, MI; Los Angeles, CA; Newark, NJ; Pittsburgh, PA; and Oakland, CA. To be eligible for the study, women were required to have an intact uterus, at least one menstrual period, and no use of reproductive hormones in the previous 3 months. The sitespecific institutional review boards of the participating institutions approved this study, and all women signed informed consent forms before participation.
Data from 608 women enrolled in SWAN Heart, an ancillary study to SWAN, were considered for this analysis. The ancillary project is a study of the natural history of subclinical atherosclerosis during the menopausal transition, involves two of the seven SWAN sites (Pittsburgh, PA, and Chicago, IL), and included African American and white women. Baseline enrollment occurred between 2001 and 2003 (corresponding to the fourth to seventh annual SWAN visits). Women were excluded if they had a history of CVD (n = 2), hysterectomy/ oophorectomy (n = 16), diabetes (n = 1), hormone therapy (n = 32), or missing menopause status (n = 17). Among the 356 women with available CRP data, an additional 49 women were excluded from this analysis because of poor waveforms, data transfer errors, or outliers (PWV 92,000 cm/s), resulting in a final sample size of 307.
Aortic PWV
Aortic PWV was measured as the distance between the carotid and femoral recording sites divided by time delay between the carotid and femoral waveforms. All measurements were done at the University of Pittsburgh Ultrasound Research Laboratory, with high reproducibility, as previously described in detail. 40 Briefly, PWV was assessed in the right carotid and femoral arteries by trained technicians using Doppler ultrasound. Participants rested in a supine position for 30 minutes before measurement. The distance between the carotid and femoral recordings was measured using a standard tape measure over the surface of the body. The time delay was calculated as the foot-to-foot time differential between simultaneously collected carotid and femoral waveforms, using the R wave of the electrocardiogram. Three runs were recorded for each participant, and usable runs were averaged.
Covariate measures
During annual visits, SWAN administered standard questionnaires, collected blood samples, and obtained anthropometric and blood pressure measures. Menopause status was assigned using self-reported bleeding histories. Premenopause status was defined as having a menstrual period in the past 3 months with no change in cycle regularity in the past 12 months. Early perimenopause status was defined as having a menstrual period in the past 3 months with some changes in cycle regularity in the past 12 months. Late perimenopause status was defined as not having a menstrual period in the past 3 months but having one in the past 12 months. Postmenopause status was defined as not having a menstrual period in the past 12 months. Because of the small sample of premenopausal (Pre; n = 25) and late perimenopausal (LP; n = 31) women, Pre women were combined with early perimenopausal (EP) women, and LP women were combined with postmenopausal (Post) women, to form a dichotomous menopause status variable (Pre/EP: 185 and LP/Post: 122) as previously reported. 25, 41 Data on self-reported smoking and alcohol use were also collected. Smoking status was dichotomized into nonsmoker versus current smoker. Participants were divided into three categories of average alcohol consumption: none to one or less drink per month, more than one drink per month to 1 drink per week, and more than two drinks per week.
Fasting blood draws were collected for measurements of lipids, glucose, insulin, and CRP. Blood samples were maintained at 4-C until separated and then frozen at j80-C and shipped on ice to Medical Research Laboratories, which is certified by the National Heart, Lung, and Blood InstituteY Centers for Disease Control and Prevention. 42 Total cholesterol and triglycerides were analyzed with the Hitachi 747 analyzer, whereas high-density lipoprotein cholesterol was isolated using heparin-2 M manganese chloride. 43, 44 Low-density lipoprotein cholesterol was calculated using the Friedewald equation. 45 Plasma glucose was measured using a hexokinasecoupled reaction (Boehringer Mannheim, Indianapolis, IN), and plasma insulin was measured using a solid-phase radioimmunoassay procedure (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA). CRP was assessed using the Behring Nephelometer II (high-sensitivity CRP on BN 100; Dade-Behring, Marburg, Germany).
Two blood pressure measurements were averaged on the right arm after 5 minutes of rest in a seated position. Weight was measured using a balance beam, digital scale, or portable scale. Body mass index was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured over undergarments or light clothing.
Statistical methods
Descriptive statistics for continuous and categorical variables were calculated for the total group and across the dichotomous menopause status variable via t test, Wilcoxon rank sum test, and W 2 . To approximate a normal distribution for CRP and glucose, a natural log transformation was preformed (log-transformed CRP [logCRP] and log-transformed glucose). Multivariable linear regression was used to test the association between PWV and logCRP while adjusting for potential confounders. Assumptions of linear regression (linearity between PWV and logCRP, independence, homoscedasticity, and normality of residuals) were tested to verify the validity of the model. Stepwise regression (slentry = 0.99 and slstay = 0.1) was used in the initial development of the most parsimonious model. Variables of interest, such as age, site, race, and menopause status, were forced into the models. Interactions between menopause status Â logCRP, menopause status Â race, logCRP Â race, and menopause status Â log-CRP Â race were tested to determine if there were differences in the PWV and logCRP association by menopause status and race. The association between logCRP tertiles (bottom tertile e0.10 mg/L, middle tertile 90.10-1.33 mg/L, top tertile 91.33 mg/L) and PWV was tested using analysis of covariance and the three-way interaction between menopause status Â logCRP Â race to demonstrate the differences in the estimated mean PWV by menopause status and race, while adjusting for confounders. Statistical significance was assessed using a type I error rate of 0.05. All analyses used SAS 9.2.
RESULTS
Population characteristics were stratified by menopause status (Table 1) . Among the 307 women, 36.8% (n = 113) were African American, and 39.7% (n = 122) were LP/Post. The proportion of African Americans was similar according to menopause status (P = 0.32). The mean (SD) age for the total group was 50.5 (2.8) years. Total cholesterol, low-density lipoprotein cholesterol, triglyceride, and glucose were all significantly greater in LP/Post women when compared with Pre/EP women. PWV was higher in LP/Post women but was only borderline significant, and after adjustment for age, PWV did not vary by menopause status. CRP was also significantly higher among LP/Post women; however, adjustment for age attenuated this difference. CRP had similar interquartile ranges for Pre/EP and LP/Post women, and the 90th percentile values of CRP were 10.7 in Pre/EP women and 9.5 mg/L in LP/Post women.
Women missing CRP or PWV data (n = 233) were similar to women included in this analysis (n = 307), except for the following: they had significantly (P G 0.05) higher systolic blood pressure (122.4 vs 117.7 mm Hg), diastolic blood pressure (78.1 vs 74.6 mm Hg), and glucose (95.6 vs 90.6) and were significantly younger (49.8 vs 50.5 years).
Cross-sectional univariate and multivariable regression models were estimated between PWV and natural logCRP ( Table 2) . Notably, for every 1-unit increase in logCRP, there was a higher estimated PWV (A = 34.4 cm/s, P G 0.0001), which was attenuated after adjustment for age, site, race, systolic blood pressure, glucose, and waist circumference (A = 15.9 cm/s, P = 0.11). In stratified analyses, adjusted models demonstrated a 36.2-cm/second higher PWV for every 1 unit of logCRP among LP/Post women (P = 0.049), whereas Pre/EP women did not have a significant linear relationship between PWV and logCRP (P = 0.61). Alcohol and smoking were not independent predictors of PWV in multivariable models, and including these two covariates in the model did not change the association between logCRP and PWV in the total or stratified analyses.
Interactions were tested to assess for possible differences in the association between PWV and CRP by menopause status and race. The unadjusted interactions between menopause status Â logCRP (P = 0.31), menopause status Â race (P = 0.061), logCRP Â race (P = 0.99), and menopause status Â logCRP Â race (P = 0.70) were not significant; however, when both the menopause status Â logCRP and menopause status Â race were included in the same model, the race interaction was significant (P = 0.041). After adjustment for age and other cardiovascular risk factors, the menopause status Â logCRP and menopause status Â race interactions were significant in their respective models (P = 0.033 for both) and borderline significant when combined into a single model (P = 0.063 and P = 0.052, repectively). Unadjusted plots of PWV by logCRP, stratified by race, display the difference in the estimated regression lines for Pre/EP versus LP/Post women, illustrating the mentioned interactions ( Fig. 1) .
To further demonstrate the influence of menopause status and race on the PWV and CRP association, the fully adjusted The differences in the adjusted mean PWV estimates by menopause status and race are presented in Figure 2 . In general, African American women had higher PWV regardless of menopause status or logCRP tertile compared with white women; however, this difference was more pronounced in the LP/Post group. Furthermore, LP/Post African American women in the top tertile of logCRP had the highest PWV on average (917 cm/s).
DISCUSSION
This study demonstrated a significant association between CRP and PWV in a cohort of women undergoing the menopausal transition. This association was significantly stronger in women who had reached late perimenopause or postmenopause status compared with those who were postmenopause or early perimenopause, suggesting that menopause modified the association between CRP and PWV. Moreover, the significant interactions between menopause status Â CRP and menopause status Â race indicated that the PWV by CRP association varied not only by menopause status but also by race. The highest PWV values were among African American women who were in the later stages of menopause and had the highest CRP levels, independent of age and known cardiovascular risk factors. These findings contribute to the current literature in that the effect of inflammation on arterial stiffness is not only age associated but also changes with the menopausal transition and varies by race. Specifically, Post African American women may benefit from CRP testing in a clinical setting for cardiovascular risk factor assessment, given the strong association with arterial stiffening above and beyond traditional risk factors.
Several studies have looked at the association between inflammation and arterial stiffness and found a positive association. 28<35 Among these, three used a population-based cohort; however, average ages were 47, 55, and 61 years, respectively, and men and women were not stratified in final models. 29, 30, 35 Therefore, conclusions regarding the associations across the menopausal transition cannot be made. Studies in which no association between PWV and CRP was observed included younger participants and Asian men and women, who are known to have lower levels of CRP. 46<48 Studies relating CRP to hypertension have also shown that the association seems stronger among older versus younger individuals. 49, 50 Several potential mechanisms could explain the relationship between inflammation and arterial stiffening. There is evidence of an increase in the expression and secretion of proinflammatory cytokines (interleukin-1, interleukin-6, and tumor necrosis factor >) with a reduction in estradiol. 21 Activation of CRP by these cytokines could inhibit endothelium-dependent vasodilation and synthesis of nitric oxide. Furthermore, this inflammation could adversely affect the collagen-to-elastin ratio of the vessel, thereby leading to arterial stiffening. 29, 30 These inflammatory-mediated vascular changes are probably occurring during a decline in estrogen as menopause progresses. Increases in vessel diameter due to menopause-induced stiffening could lead to an increase in tensile stress, which would make the vessel more susceptible to risk factors for increased inflammation. 24, 25 This analysis found a significant interaction between CRP and menopause status in the combined African American and white group, suggesting that menopause in strengthening the association between CRP and PWV independent of age. When women were stratified by race, this pattern remained FIG. 2. Adjusted mean pulse wave velocity estimates by C-reactive protein tertiles, menopause status, and race. logCRP tertiles are as follows: bottom, 0.10 mg/L or less; middle, more than 0.10 to 1.33 mg/L; top, more than 1.33 mg/L. Estimated pulse wave velocity means were generated using an analysis of covariance and the three-way interaction between menopause status Â logCRP Â race, adjusted for site (Pittsburgh vs Chicago), age (years), race (African American vs white), SBP (mmHg), natural log-transformed glucose (mg/dL), and waist circumference (cm). Pre/EP, premenopausal/early perimenopausal; LP/Post, late perimenopausal/postmenopausal; logCRP, log-transformed C-reactive protein; SBP, systolic blood pressure.
among African American women but was lost for white women. Studies exploring racial differences in inflammation have consistently found higher levels of CRP among African American participants compared with white participants. 48 ,51<54 This observation may be related to differences in adipose tissue distribution, mental health, socioeconomic status, and discrimination. 51<53,55 There is a question of whether CRP is a valuable predictor of CVD risk in women younger than 60 years; however, studies suggest that using inflammatory markers may reclassify African American participants into higher risk categories more often compared with white participants. 19, 56 Findings from this SWAN Heart analysis suggest that inflammation may be related to arterial stiffening more strongly among women later in the menopausal transition and possibly even more so among African American women. This potential difference is important because as women age and transition through menopause, the risk of cardiovascular events increases. Furthermore, higher CRP and the interaction between inflammation, race, hormones, and changes in the vasculature as women age may explain racial differences in cardiovascular risk. Inherent in any cross-sectional design is the inability to determine causality. Thus, it cannot be ascertained whether increased inflammation results in increased arterial stiffening or vice versa. The associations observed in this study were independent of known confounders, such as age and cardiovascular risk factors, including alcohol and smoking. 57, 58 In addition, given the similar CRP ranges between Pre/EP and LP/Post women, it is less likely that the findings in this study were simply due to higher CRP levels among women later in the menopausal transition. Hormone therapy users were excluded from the analyses because of the small sample size and lack of power to detect an effect of hormone therapy on the association by menopause status. Further research will need to explore the effects of hormone therapy on arterial stiffening and inflammation. Finally, the relatively small sample size when stratified by menopause status and race limited the power to fully investigate the role of race in Post women (African American women by logCRP tertile, respectively, n = 11 and 16, 22; Fig. 2 ). Larger sample sizes are needed to fully evaluate the racial differences in inflammation and arterial stiffening.
CONCLUSIONS
This study contributes to the current body of literature because it explores a potential mechanism explaining the increased CVD in women who are later in their menopausal transition. It is likely that menopause is associated with an increase in inflammation, which, in turn, results in increased stiffening of the vasculature and increased risk of cardiovascular outcomes. Moreover, racial differences in this association probably exist, and therefore, the utility of CRP predicting CVD risk may need to be tailored to the individual woman based not only on age but also on menopause status and race. There is evidence that inflammation and arterial stiffening can be tempered with medication, physical activity, and healthy lifestyles; therefore, it is likely that the menopause-associated increase in cardiovascular risk can be reduced through these strategies. 59<63 
